Main characteristics of the patients evaluable for response (n = 64) at the entry of the trial
| Variables . | Distribution, n (%) . |
|---|---|
| Age, y | |
| <60 | 32 (50) |
| 60-70 | 32 (50) |
| Gender | |
| Female | 19 (30) |
| Male | 45 (70) |
| Binet stage | |
| A | 9 (14) |
| B | 39 (61) |
| C | 16 (25) |
| Rai Stage | |
| 0 | 3 (5) |
| I-II | 43 (67) |
| III-IV | 18 (28) |
| Lymphocyte count | |
| <100 000/µL | 45 (70) |
| ≥100 000/µL | 19 (30) |
| LDT, n = 55 | |
| >12 mo | 29 (53) |
| ≤12 mo | 26 (47) |
| Serum LDH, n = 61 | |
| Normal | 45 (74) |
| Increased | 16 (26) |
| β2-microglobulin, n = 60 | |
| Normal | 20 (33) |
| Increased | 40 (67) |
| Genetic abnormalities, n = 51 | |
| del(13q) | 12 (23) |
| +12 | 6 (12) |
| del(11q) | 7 (14) |
| del(17p) | 2 (4) |
| ZAP-70 expression, n = 59 | |
| <20% | 24 (41) |
| ≥20% | 35 (59) |
| Response to R-FCM induction | |
| CR MRD− | 35 (55) |
| CR MRD+ | 21 (33) |
| PR | 8 (12) |
| Variables . | Distribution, n (%) . |
|---|---|
| Age, y | |
| <60 | 32 (50) |
| 60-70 | 32 (50) |
| Gender | |
| Female | 19 (30) |
| Male | 45 (70) |
| Binet stage | |
| A | 9 (14) |
| B | 39 (61) |
| C | 16 (25) |
| Rai Stage | |
| 0 | 3 (5) |
| I-II | 43 (67) |
| III-IV | 18 (28) |
| Lymphocyte count | |
| <100 000/µL | 45 (70) |
| ≥100 000/µL | 19 (30) |
| LDT, n = 55 | |
| >12 mo | 29 (53) |
| ≤12 mo | 26 (47) |
| Serum LDH, n = 61 | |
| Normal | 45 (74) |
| Increased | 16 (26) |
| β2-microglobulin, n = 60 | |
| Normal | 20 (33) |
| Increased | 40 (67) |
| Genetic abnormalities, n = 51 | |
| del(13q) | 12 (23) |
| +12 | 6 (12) |
| del(11q) | 7 (14) |
| del(17p) | 2 (4) |
| ZAP-70 expression, n = 59 | |
| <20% | 24 (41) |
| ≥20% | 35 (59) |
| Response to R-FCM induction | |
| CR MRD− | 35 (55) |
| CR MRD+ | 21 (33) |
| PR | 8 (12) |